The promotion of antitumor immunity by CXCR4-antagonists was reported for a mouse model of ovarian cancer (226) and in an orthotopic preclinical hepatocellular carcinoma (HCC) model where a CXCR4 antagonist was combined with a checkpoint inhibitor. This evidence concerns the gene CXCR4 and ovarian carcinoma.